Drug Profile
CVX 045
Alternative Names: CovX 045; CVX-045; PF-4856882Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CovX
- Developer Pfizer
- Class Antibodies; Peptides
- Mechanism of Action Thrombospondin 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Solid tumours in USA (Parenteral)
- 28 Feb 2007 Phase-I clinical trials in Solid tumours in USA (Parenteral)